Market Size
The Global Hyperopia Treatment Market reached US$ 3,427.36 million in 2024 and is expected to reach US$ 6,651.86 million by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033.
Executive Summary
Hyperopia, a prevalent refractive condition in both children and adults, requires regular assessment and treatment to prevent future complications. Adult hyperopia is linked to certain issues, necessitating regular assessment. This activity reviews hyperopia evaluation and management for long-term prevention.
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Growing Prevalence of Hyperopia
One of the primary factors driving the hyperopia treatment market is the increasing prevalence of hyperopia, particularly among the elderly population. Presbyopia and hyperopia are conditions that result from the natural deterioration of the eye's lens, which impairs the ability of individuals to focus on adjacent objects as they age.
For instance, pathologic hyperopia is considerably less prevalent than physiologic (Simple and Functional) hyperopia. A reduction in axial length most frequently causes hyperopia. The United States has an overall prevalence of hyperopia of approximately 10%, translating to approximately 14 million individuals. Mild hyperopia is a condition that affects the majority of full-term neonates. Approximately 4-9% of infants are hyperopic by the age of 6-9 months, and the prevalence is approximately 3.6% by the age of 12 months.
Hence, the increasing prevalence of hyperopia, particularly among the elderly, which drives demand for corrective solutions like eyeglasses, contact lenses, and refractive surgeries with around 10% of the U.S. population affected, the need for effective treatment options continues to grow.
Risk of Post-Treatment Complications and Side Effects
The hyperopia treatment market faces challenges due to the risk of post-treatment complications and side effects from surgical interventions like LASIK, PRK, and lens implantation. These risks can lead to adverse effects like dry eyes, glare, halos and vision regression, increasing the cost and recovery time. This discourages patients from considering advanced hyperopia treatments, limiting their adoption and impacting market growth.
For instance, according to NCBI recent studies indicate that corrective lenses effectively manage hyperopia, but surgical treatments require careful patient selection and counseling due to potential side effects.
Market Segment Analysis
The global hyperopia treatment market is segmented based on type, treatment type, age group, end user and region.
Treatment Type:
Eye Glasses & Contact Lenses in the treatment type segment is expected to dominate the hyperopia treatment with the highest market share
Hyperopia can be corrected using aspheric high-index lenses or spherical lenses, depending on the strength of the prescription. High-index lenses are thinner and lighter, with a slimmer profile. Anti-reflective coatings are recommended for glasses. Spherical lenses can also correct hyperopia. Wearing options include daily disposable and weekly or monthly contact lenses. Eye Glasses and contact lens prescriptions for farsightedness usually start with plus numbers. Both lenses are suitable for higher prescriptions and offer a slimmer profile.
For instance, Johnson & Johnson Vision Care has approved ACUVUE Theravision with Ketotifen, an etafilcon A drug-eluting contact lens with ketotifen. The FDA-approved lenses contain 19 mcg of ketotifen, an established antihistamine. This marks the first in a new category of contact lenses for those with allergic eye itch, offering a new wearing experience.
Moreover, both contact lenses and eyeglasses contribute to the correction of refractive errors by altering the manner in which light is reflected and bent into the retina. Typically, eyeglasses that correct for farsightedness are larger in the midsection because they are often correcting for a "plus prescription" and a cornea that is too flat. If the prescription is substantial, this may result in a magnified or "bug eye" appearance.
Market Geographical Share
North America is expected to hold a significant position in the hyperopia treatment market with highest market share
North America holds a substantial position in the hyperopia treatment market and is expected to hold most of the market share owing to FDA approvals, advanced healthcare infrastructure, advanced technologies and rising awareness. The aging population, ophthalmic device manufacturers, and favorable reimbursement policies contribute to market growth. The surge in customized procedures and premium intraocular lenses strengthens the market.
For instance, in January 2025, the U.S. FDA approved the excimer laser MEL 90 from Zeiss Meditech for myopia, hyperopia and mixed astigmatism. The laser integrates into Zeiss' Corneal Refractive Workflow, complementing Visumax 800 and SMILE pro software, ensuring efficient surgical correction with positive outcomes.
Hence, the FDA has approved the Zeiss Meditech MEL 90 excimer laser, boosting the hyperopia treatment market by expanding surgical options, improving procedural efficiency, and precision, thus driving innovation and adoption of laser-based hyperopia treatments.
Major Global Players
The major global players in the hyperopia treatment market include Zeimer Ophthalmic Systems AG, Carl Zeiss Meditec AG, ALCON Inc, Bausch Health Companies Inc, Johnson & Johnson Vision, NIDEK CO. LTD, Essilor Luxottica (Essilor Ltd), the Cooper Companies Inc, Ophtec, Staar Surgical and among others.
Key Developments
- In August 2024, ZEISS Medical Technology unveiled its latest cataract and corneal refractive workflow innovations at the European Society of Cataract and Refractive Surgeons (ESCRS) conference. The company is the first to offer hyperopia treatment with lenticule extraction using SMILE pro in CE markets. ZEISS also celebrates surpassing the 10 million marks for lenticule extraction procedures with ZEISS SMILE and ZEISS SMILE pro. The company will introduce advanced optical and digital ophthalmic microscopes and showcase its enhanced IOL portfolio.
| Metrics | Details | |
| CAGR | 7.5% | |
| Market Size Available for Years | 2018-2033 | |
| Estimation Forecast Period | 2025-2033 | |
| Revenue Units | Value (US$ Mn) | |
| Volume (Units) | ||
| Segments Covered | Type | Axial Hyperopia, Curvature Hyperopia, Index Hyperopia, Positional Hyperopia |
| Treatment Type | Eye Glasses & Contact Lenses, Refractive Surgery | |
| Age Group | Pediatric, Adults, Geriatric | |
| End-User | Hospitals, Ophthalmic Clinics & Eye Care Centers, Ambulatory Surgical Centers (ASCs), Retail & Online Optical Stores | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa | |
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
Target Audience 2024
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
The global hyperopia treatment market report delivers a detailed analysis with 61 key tables, more than 59 visually impactful figures, and 220 pages of expert insights, providing a complete view of the market landscape.
